WO1997025059A1 - Using serine-proteases for acne and inflamed comedones - Google Patents

Using serine-proteases for acne and inflamed comedones Download PDF

Info

Publication number
WO1997025059A1
WO1997025059A1 PCT/EP1996/005703 EP9605703W WO9725059A1 WO 1997025059 A1 WO1997025059 A1 WO 1997025059A1 EP 9605703 W EP9605703 W EP 9605703W WO 9725059 A1 WO9725059 A1 WO 9725059A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
preparations
derivatives
acne
weight
Prior art date
Application number
PCT/EP1996/005703
Other languages
German (de)
French (fr)
Inventor
Michael Christiansen
Andreas Herpens
Uwe SCHÖNROCK
Sigrid Steinke
Sven Untiedt
Original Assignee
Beiersdorf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf Ag filed Critical Beiersdorf Ag
Priority to EP96944009A priority Critical patent/EP0876154A1/en
Priority to JP9524791A priority patent/JP2000502717A/en
Publication of WO1997025059A1 publication Critical patent/WO1997025059A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to active substances and preparations containing active substances which are effective against impure skin or acne.
  • Propionibacterium acnes is one of the most important microorganisms which is associated with impure skin.
  • Impure skin and / or comedones affect the well-being of those affected, even in mild cases. Since practically every young person is affected by impure skin of any kind. there is a need for many people to remedy this condition.
  • the object of the present invention was therefore to find a substance which is effective against impure skin or acne.
  • serine proteinases In the active center, serine proteinases contain an L-serine residue which is essential for catalysis and which is part of the so-called catalytic triad (consisting of three amino acids). that come close to each other in the tertiary structure of the enzymes.
  • An L-histidine residue acts as an acceptor for the proton of the OH group of the serine, which attacks the protein nucleophilically during catalysis.
  • An L-aspartate residue has a stabilizing effect on the transition state.
  • protease from Novo Nordisk A / S, Bagsvasrd. Denmark, is available under the name "SP 544 Protease”.
  • antioxidants can be used in combination with serine proteinases, all antioxidants suitable or customary for cosmetic and / or dermatological applications being advantageous according to the invention.
  • the antioxidants are preferably selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-camosine. D-camosin, L-camosin and their derivatives (eg anserine), carotenoids.
  • Carotenes e.g. ⁇ -caratin, ⁇ -carotene, lycopene
  • lipoic acid and their derivatives e.g. dihydroliponic acid
  • aurothioglucose propylthiouracil and other thiols
  • thioredoxin glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyh methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -Linoleyh cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyrthodipropionate, thiodipropionic acid and their derivatives (esters, Ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g.
  • buthioninsulfoximines homocysteine sulfoximine, buthioninsulfones, penta-, hexa-, heptathioninsulfoximine) in very low tolerable dosages (e.g. pmol to ⁇ mol / kg), further ( Metal) chelators (e.g. ⁇ -hydroxyfatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (e.g.
  • the amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1-10% by weight, based on the total weight the preparation.
  • vitamin E and / or its derivatives represent the antioxidant (s)
  • anti-acne substances or anti-inflammatory agents for example batyl alcohol ( ⁇ -octadecylglyceryl ether), Seiachyl alcohol ( ⁇ -9-octadecenylglyceryl ether), chimyl alcohol ( ⁇ -hexadecylglyceryl ether) and / or bisabolol.
  • batyl alcohol ⁇ -octadecylglyceryl ether
  • Seiachyl alcohol ⁇ -9-octadecenylglyceryl ether
  • chimyl alcohol ⁇ -hexadecylglyceryl ether
  • bisabolol for example batyl alcohol ( ⁇ -octadecylglyceryl ether), Seiachyl alcohol ( ⁇ -9-octadecenylglyceryl ether), chimyl alcohol ( ⁇ -hexadecylglyceryl ether) and / or bisabolo
  • compositions are usually inconceivable without the usual hoof and additives.
  • these include, for example, consistency agents, fillers, perfume, dyes, emulsifiers, additional active ingredients such as vitamins or proteins, light stabilizers, stabilizers, antioxidants, insect repellents, alcohol, water, salts, antimicrobial, proteolytic or keratolytically active substances, etc.
  • buffer substances to the preparations used according to the invention. It is particularly advantageous if the preparations are buffered to pH values of 6.5 or less, in particular 6.0.
  • the cosmetic and dermatological preparations according to the invention are applied to the skin in a sufficient amount in the manner customary for cosmetics.
  • Cosmetic and dermatological preparations used according to the invention can exist in various forms, such as those e.g. are usually used for this type of preparations. So you can e.g. a solution, an emulsion of the type water-in-oil (W / O) or of the type oil-in-water (O / W), or a multiple emulsions, for example of the type water-in-oil-in-water (W / O / W), a gel, a solid stick or an aerosol.
  • the cosmetic and dermatological preparations used according to the invention can contain cosmetic auxiliaries, as are usually used in such preparations, e.g. Preservatives, bactericides, perfumes, substances to prevent foaming, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other usual constituents a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
  • cosmetic auxiliaries e.g. Preservatives, bactericides, perfumes, substances to prevent foaming, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other usual constituents a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam
  • the cosmetic or dermatological preparation used according to the invention is a solution or lotion
  • the following can be used as solvents: water or aqueous solutions
  • Oils such as triglycerides of capric or caprylic acid, but preferably castor oil;
  • Fats, waxes and other natural and synthetic fat bodies preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids;
  • Alcohols, diols or polyols of low C number, and their ethers preferably ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl. monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and similar products.
  • Water can also be a component of alcoholic solvents.
  • Emulsions used according to the invention are advantageous and contain e.g. the said fats, oils, waxes and other fat bodies, as well as water and an emulsifier, as is usually used for such a type of formulation.
  • Preparations used according to the invention can also advantageously be present as gels which, in addition to the active compound combinations according to the invention and solvents usually used for them, usually alcohols of low C number, e.g. Ethanol, isopropanol, 1,2-propanediol, glycerol and water or an oil mentioned above, then also contain organic thickeners, e.g. Gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or inorganic thickeners, e.g.
  • organic thickeners e.g. Gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or inorganic thickeners, e.
  • Silicon dioxide and / or aluminum silicates such as bentonites, for example, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
  • the thickener (s) are in the gel e.g. in an amount between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.
  • Solid sticks used according to the invention contain, for example, natural or synthetic waxes, fatty alcohols or fatty acid esters.
  • the cosmetic or dermatological preparations used according to the invention preferably contain 0.0001-5.00% by weight of one or more serine proteinases, based on the total weight of the preparations.
  • substances which are active against acne for example substances which are active against Propionibacterium acnes (for example those described in DE-OS 42 29 707, DE-OS 43 05 069, DE-OS 43 07 976,) DE-OS 43 37 711, DE-OS 43 29 379) but also other substances which act against acne, for example all-trans-retinoic acid.
  • 13-cis-retinoic acid and related substances or anti-inflammatory agents, for example batyl alcohol ( ⁇ -octadecylglyceryl ether), selachyl alcohol ( ⁇ -9-octadecenylglyceryl ether), chimyl alcohol ( ⁇ -hexadecylglyceryl ether) and / or bisabolol.
  • batyl alcohol ⁇ -octadecylglyceryl ether
  • selachyl alcohol ⁇ -9-octadecenylglyceryl ether
  • chimyl alcohol ⁇ -hexadecylglyceryl ether
  • the preparations can preferably also contain substances which absorb UV radiation in the UVB range, the total amount of filter substances e.g. 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, in particular 1 to 6% by weight, based on the total weight of the preparations, in order to prepare cosmetic and / or dermatological preparations To provide that protect the skin from the entire range of ultraviolet radiation.
  • the total amount of filter substances e.g. 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, in particular 1 to 6% by weight, based on the total weight of the preparations, in order to prepare cosmetic and / or dermatological preparations To provide that protect the skin from the entire range of ultraviolet radiation.
  • UVB filter substances if they contain UVB filter substances, they can be oil-soluble or water-soluble.
  • Oil-soluble UVB filters which are advantageous according to the invention are, for example:
  • 3-benzylidene camphor derivatives e.g. 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
  • 4-aminobenzoic acid derivative ⁇ e.g. 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • esters of cinnamic acid e.g. 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
  • esters of salicylic acid e.g. Salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomethyl ester,
  • benzophenone e.g. 2-hydroxy-4-methoxybenzophenone, 2-hydroxy
  • Esters of benzalmalonic acid for example 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester, 2,4,6-trianilino- (p-carbo-2'-ethyl-1'-hexyloxy) -1,3,5-triazine.
  • Triethanolammonium salt as well as the sulfonic acid itself
  • Sulfonic acid derivatives of 3-benzylidene camphor e.g. 4- (2-oxo-3-bornylidene-methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidene-methyl) sulfonic acid and their salts.
  • UVA filter substances these can advantageously be selected according to the invention from the group of the derivatives of dibenzoyimethane, e.g. 1- (4'-tert-Butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione and 1-phenyl-3- (4'-isopropylphenyl) propane-1,3-dione.
  • the preparations used according to the invention can also contain further inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of titanium, iron, zirconium, silicon, manganese, aluminum, cerium and mixtures or modifications thereof. It is particularly preferred to use pigments based on titanium dioxide.
  • Water can also be a component of alcoholic solvents.

Abstract

This invention concerns the use of serine-proteases for controlling the development of impure skin or acne.

Description

Beschreibung description
Verwendung von Serin-Proteinasen gegen Akne und entzündete ComedonenUse of serine proteinases against acne and inflamed comedones
Die vorliegende Erfindung betrifft Wirkstoffe und Zubereitungen, solche Wirkstoffe ent¬ haltend, welche gegen unreine Haut bzw. Akne wirksam sind.The present invention relates to active substances and preparations containing active substances which are effective against impure skin or acne.
Bei der unreinen Haut sind neben anderen Einflüssen bakterielle Sekundärinfektionen von ätiologischer Bedeutung. Einer der wichtigsten Mikroorganismen, der in Zusammen¬ hang mit unreiner Haut steht, ist Propionibacterium acnes.In the case of blemished skin, bacterial secondary infections are of etiological importance in addition to other influences. Propionibacterium acnes is one of the most important microorganisms which is associated with impure skin.
Unreine Haut und/oder Komedonen beeinträchtigen das Wohlbefinden der Betroffenen aber selbst in leichten Fällen. Da praktisch jeder oder jede Jugendliche von unreiner Haut irgendeiner Ausprägung betroffen ist. besteht bei vielen Personen Bedarf, diesem Zustande abzuhelfen.Impure skin and / or comedones affect the well-being of those affected, even in mild cases. Since practically every young person is affected by impure skin of any kind. there is a need for many people to remedy this condition.
Beim Vollbilde der Akne, aber auch bei leichteren Ausprägungen, sind Entzündungen der Aknepusteln häufige Folge. Der Stand der Technik ließ es an Wirkstoffen, die eine befriedigende Behandlung im Sinne einer Heilung mangeln.Inflammation of the acne pustules is a common consequence of full-blown acne, but also of lighter forms. The prior art left it to active ingredients that lack satisfactory treatment in the sense of a cure.
Aufgabe der vorliegenden Erfindung war es also, einen gegen unreine Haut bzw. Akne wirksamen Stoff zu finden.The object of the present invention was therefore to find a substance which is effective against impure skin or acne.
Es hat sich überraschenderweise gezeigt, und darin liegt die Lösung der Aufgabe, daß die Verwendung von Serin-Proteinasen gegen das Erscheinungsbild der unreinen Haut bzw. der Akne den Nachteilen des Standes der Technik abhilft. Zwar wird in der Schrift WO 93/19731 die Verwendung von Proteasen gegen - unter an¬ derem - Akne beschrieben, die a.a.O. beschriebenen Proteasen legten jedoch nicht die vorteilhaften Eigenschaften der erfindungsgemäß verwendeten Serin-Proteinasen.It has surprisingly been found, and this is the solution to the problem that the use of serine proteinases against the appearance of blemished skin or acne remedies the disadvantages of the prior art. Although the use of proteases against - among other things - acne is described in the document WO 93/19731, the above-mentioned proteases did not establish the advantageous properties of the serine proteinases used according to the invention.
Serin-Proteinasen enthalten im aktiven Zentrum einen für die Katalyse essentiellen L- Serin-Rest, welcher Teil der sogenannten katalytischen Triade (aus drei Aminosäuren) ist. die einander in der Tertiärstruktur der Enzyme nahekommen. Ein L-Histidinrest agiert als Akzeptor für das Proton der OH-Gruppe des Serins, welches bei der Katalyse das Protein nucleophil angreift. Ein L-Aspartatrest wirkt stabilisierend auf den Übergangs¬ zustand.In the active center, serine proteinases contain an L-serine residue which is essential for catalysis and which is part of the so-called catalytic triad (consisting of three amino acids). that come close to each other in the tertiary structure of the enzymes. An L-histidine residue acts as an acceptor for the proton of the OH group of the serine, which attacks the protein nucleophilically during catalysis. An L-aspartate residue has a stabilizing effect on the transition state.
Erfindungsgemäß günstig zu verwenden st beispielsweise eine Protease die von der Gesellschaft Novo Nordisk A/S, Bagsvasrd. Dänemark, unter der Bezeichnung „SP 544 Protease" erhältlich ist.According to the invention, it is inexpensive to use, for example, a protease from Novo Nordisk A / S, Bagsvasrd. Denmark, is available under the name "SP 544 Protease".
Erfindungsgemäß günstig, aber dennoch fakultativ können Antioxidantien in Kombinati¬ on mit Serin-Proteinasen verwendet werden, wobei alle für kosmetische und/oder der¬ matologische Anwendungen geeigneten oder gebräuchlichen Antioxidantien erfindungs¬ gemäß vorteilhaft in Betracht kommen.Inexpensive according to the invention, but nevertheless optionally, antioxidants can be used in combination with serine proteinases, all antioxidants suitable or customary for cosmetic and / or dermatological applications being advantageous according to the invention.
Bevorzugt werden die Antioxidantien gewählt aus der Gruppe bestehend aus Aminosäu¬ ren (z.B. Glycin, Histidin, Tyrosin, Tryptophan) und deren Derivate, Imidazole (z.B. Uro- caninsäure) und deren Derivate, Peptide wie D,L-Camosin. D-Camosin, L-Camosin und deren Derivate (z.B. Anserin), Carotinoide. Carotine (z.B. α-Caratin, ß-Carotin, Lycopin) und deren Derivate, Liponsäure und deren Derivate (z.B. Dihydroliponsäure), Aurothio- glucose, Propylthiouracil und andere Thiole (z.B. Thioredoxin, Glutathion, Cystein, Cystin, Cystamin und deren Glycosyl-, N-Acetyh Methyl-, Ethyl-, Propyl-, Amyl-, Butyl- und Lauryl-, Palmitoyl-, Oleyl-, γ-Linoleyh Cholesteryl- und Glycerylester) sowie deren Salze, Dilaurylthiodipropionat, Distearyrthtodipropionat, Thiodipropionsäure und deren Derivate (Ester, Ether, Peptide, Lipide, Nukleotide, Nukleoside und Salze) sowie Sulf- oximinverbindungen (z.B. Buthioninsulfoximine, Homocysteinsulfoximin, Buthioninsul- fone, Penta-, Hexa-, Heptathioninsulfoximin) in sehr geringen verträglichen Dosierungen (z.B. pmol bis μmol/kg), ferner (Metall)-Chelatoren (z.B. α-Hydroxyfettsäuren, Palmitin- säure, Phytinsäure, Lactoferrin), α-Hydroxysäuren (z.B. Zitronensäure, Milchsäure, Ap¬ felsäure), Huminsäure, Gallensäure, Gallenextrakte, Bilirubin, Biliverdin, EDTA, EGTA und deren Derivate, ungesättigte Fettsäuren und deren Derivate (z.B. γ-Linolensäure, Li¬ nolsäure, Ölsäure), Folsäure und deren Derivate, Ubichinon und Ubichinol und deren Derivate, Vitamin C und Derivate (z.B. Ascorbylpalmitat, Mg-Ascorbylphosphat, Ascor- bylacetat), Tocopherole und Derivate (z.B. Vitamin-E-acetat), sowie Koniferylbenzoat des Benzoeharzes, Rutinsäure und deren Derivate, Ferulasäure und deren Derivate, Butylhydroxytoluol, Butylhydroxyanisol, Nordihydroguajakharzsäure, Nordihydro- guajaretsäure, Trihydroxybutyrophenon, Harnsäure und deren Derivate, Mannose und deren Derivate, Zink und dessen Derivate (z.B. ZnO, ZnSθ4) Selen und dessen De¬ rivate (z.B. Selenmethionin), Stilbene und deren Derivate (z.B. Stilbenoxid, Trans-Stil- benoxid) und die erfindungsgemäß geeigneten Derivate (Salze, Ester, Ether, Zucker, Nukleotide, Nukleoside, Peptide und Lipide) dieser genannten Wirkstoffe.The antioxidants are preferably selected from the group consisting of amino acids (eg glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg urocanic acid) and their derivatives, peptides such as D, L-camosine. D-camosin, L-camosin and their derivatives (eg anserine), carotenoids. Carotenes (e.g. α-caratin, β-carotene, lycopene) and their derivatives, lipoic acid and their derivatives (e.g. dihydroliponic acid), aurothioglucose, propylthiouracil and other thiols (e.g. thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyh methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γ-Linoleyh cholesteryl and glyceryl esters) and their salts, dilauryl thiodipropionate, distearyrthodipropionate, thiodipropionic acid and their derivatives (esters, Ethers, peptides, lipids, nucleotides, nucleosides and salts) as well as sulfoximine compounds (e.g. buthioninsulfoximines, homocysteine sulfoximine, buthioninsulfones, penta-, hexa-, heptathioninsulfoximine) in very low tolerable dosages (e.g. pmol to μmol / kg), further ( Metal) chelators (e.g. α-hydroxyfatty acids, palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (e.g. citric acid, lactic acid, apple acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (eg γ-linolenic acid, linoleic acid, oleic acid), folic acid and their derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and derivatives (eg ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate) , Tocopherols and derivatives (eg vitamin E acetate), as well as coniferyl benzoate of benzoin, rutinic acid and its derivatives, ferulic acid and its derivatives, butylhydroxytoluene, butylhydroxyanisole, nordihydroguajak resin acid, nordihydroguajaretic acid, trihydroxybutyrophenon derivate, uric acid, mannic acid Zinc and its derivatives (eg ZnO, ZnSO4) selenium and its derivatives (eg selenium methionine), stilbenes and their derivatives (eg stilbene oxide, trans-stilbene oxide) and the derivatives suitable according to the invention (salts, esters, ethers, sugars, nucleotides) , Nucleosides, peptides and lipids) of these active ingredients.
Die Menge der Antioxidantien (eine oder mehrere Verbindungen) in den Zubereitungen beträgt vorzugsweise 0,001 bis 30 Gew.-%, besonders bevorzugt 0,05 - 20 Gew.-%, ins¬ besondere 1 - 10 Gew.-%, bezogen auf das Gesamtgewicht der Zubereitung.The amount of the antioxidants (one or more compounds) in the preparations is preferably 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1-10% by weight, based on the total weight the preparation.
Sofern Vitamin E und/oder dessen Derivate das oder die Antioxidantien darstellen, ist vorteilhaft, deren jeweilige Konzentrationen aus dem Bereich von 0,001 - 10 Gew.-%, bezogen auf das Gesamtgewicht der Formulierung, zu wählen.If vitamin E and / or its derivatives represent the antioxidant (s), it is advantageous to choose their respective concentrations from the range of 0.001-10% by weight, based on the total weight of the formulation.
Es ist vorteilhaft, den erfindungsgemäß verwendeten Zubereitungen weitere gegen Akne wirksame Substanzen oder antientzündliche Wirkstoffe zuzugeben, beispiels¬ weise Batylalkohol (α-Octadecylglycerylether), Seiachylalkohol (α-9-Octadecenylgly- cerylether), Chimylalkohol (α-Hexadecylgiycerylether) und/oder Bisabolol.It is advantageous to add further anti-acne substances or anti-inflammatory agents to the preparations used according to the invention, for example batyl alcohol (α-octadecylglyceryl ether), Seiachyl alcohol (α-9-octadecenylglyceryl ether), chimyl alcohol (α-hexadecylglyceryl ether) and / or bisabolol.
Es ist dem Fachmanne natürlich bekannt, daß anspruchsvolle kosmetische Zusammen¬ setzungen zumeist nicht ohne die üblichen Hufs- und Zusatzstoffe denkbar sind. Dar¬ unter zählen beispielsweise Konsistenzgeber, Füllstoffe, Parfüm, Farbstoffe, Emulgato¬ ren, zusätzliche Wirkstoffe wie Vitamine oder Proteine, Lichtschutzmittel, Stabilisatoren, Antioxidantien, Insektenrepellentien, Alkohol, Wasser, Salze, antimikrobiell, proteolytisch oder keratolytisch wirksame Substanzen usw.It is of course known to the person skilled in the art that sophisticated cosmetic compositions are usually inconceivable without the usual hoof and additives. These include, for example, consistency agents, fillers, perfume, dyes, emulsifiers, additional active ingredients such as vitamins or proteins, light stabilizers, stabilizers, antioxidants, insect repellents, alcohol, water, salts, antimicrobial, proteolytic or keratolytically active substances, etc.
Es ist von Vorteil, den Wassergehalt der Formulierungen geringer als 65 Gew.-% und den Alkoholgehalt geringer als 20 Gew.-% zu halten. Ferner hat es sich als bevorzugt herausgestellt, den Gehalt an Chelatbildnern so gering wie möglich zu halten, möglichst ganz auf Chelatbildner zu verzichten.It is advantageous to keep the water content of the formulations below 65% by weight and the alcohol content below 20% by weight. It has also been preferred emphasized to keep the content of chelating agents as low as possible, to do without chelating agents as far as possible.
Es ist besonders vorteilhaft, den erfindungsgemäß verwendeten Zubereitungen Puffer¬ substanzen zuzufügen. Insbesondere vorteilhaft ist, wenn die Zubereitungen auf pH- Werte von 6,5 oder kleiner, insbesondere 6.0, abgepuffert werden.It is particularly advantageous to add buffer substances to the preparations used according to the invention. It is particularly advantageous if the preparations are buffered to pH values of 6.5 or less, in particular 6.0.
Zur Anwendung werden die erfindungsgemäßen kosmetischen und dermatologischen Zubereitungen in der für Kosmetika üblichen Weise auf die Haut in ausreichender Men¬ ge aufgebracht.For use, the cosmetic and dermatological preparations according to the invention are applied to the skin in a sufficient amount in the manner customary for cosmetics.
Erfindungsgemäß verwendete kosmetische und dermatologische Zubereitungen können in verschiedenen Formen vorliegen, wie sie z.B. üblicherweise für diesen Typ von Zube¬ reitungen eingesetzt werden. So können sie z.B. eine Lösung, eine Emulsion vom Typ Wasser-in-ÖI (W/O) oder vom Typ Öl-in-Wasser (O/W), oder eine multiple Emulsionen, beispielsweise vom Typ Wasser-in-ÖI-in-Wasser (W/O/W), ein Gel, einen festen Stift oder auch ein Aerosol darstellen.Cosmetic and dermatological preparations used according to the invention can exist in various forms, such as those e.g. are usually used for this type of preparations. So you can e.g. a solution, an emulsion of the type water-in-oil (W / O) or of the type oil-in-water (O / W), or a multiple emulsions, for example of the type water-in-oil-in-water (W / O / W), a gel, a solid stick or an aerosol.
Es ist auch möglich und vorteilhaft im Sinne der vorliegenden Erfindung, die erfindungs¬ gemäß verwendeten Serin-Proteinasen in wäßrige Systeme bzw. Tensidzubereitungen zur Reinigung der Haut einzufügen.It is also possible and advantageous for the purposes of the present invention to insert the serine proteinases used according to the invention into aqueous systems or surfactant preparations for cleaning the skin.
Die erfindungsgemäß verwendeten kosmetischen und dβrmatologischen Zubereitungen können kosmetische Hilfsstoffe entharten, wie sie üblicherweise in solchen Zubereitun¬ gen verwendet werden, z.B. Konservierungsmittel, Bakterizide, Parfüme, Substanzen zum Verhindern des Schäumens, Farbstoffe, Pigmente, die färbende Wirkung haben, Verdickungsmittel, oberflächenaktive Substanzen, Emulgatoren, weichmachende, an¬ feuchtende und/oder feuchthaltende Substanzen, Fette, Öle, Wachse oder andere übli¬ che Bestandteile einer kosmetischen oder dermatolog ischen Formulierung wie Alkohole, Polyole, Polymere, Schaumstabilisatoren, Elektrolyte, organische Lösungsmittel oder Silikonderivate.The cosmetic and dermatological preparations used according to the invention can contain cosmetic auxiliaries, as are usually used in such preparations, e.g. Preservatives, bactericides, perfumes, substances to prevent foaming, dyes, pigments that have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other usual constituents a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, electrolytes, organic solvents or silicone derivatives.
Sofern die erfindungsgemäß verwendete kosmetische oder dermatologische Zuberei¬ tung eine Lösung oder Lotion darstellt, können als Lösemittel verwendet werden: Wasser oder wäßrige Lösungen Öle, wie Triglyceride der Caprin- oder der Caprylsäure, vorzugsweise aber Rizi¬ nusöl;If the cosmetic or dermatological preparation used according to the invention is a solution or lotion, the following can be used as solvents: water or aqueous solutions Oils, such as triglycerides of capric or caprylic acid, but preferably castor oil;
Fette, Wachse und andere natürliche und synthetische Fettkörper, vorzugsweise Ester von Fettsäuren mit Alkoholen niedriger C-Zahl, z.B. mit Isopropanol, Propy¬ lenglykol oder Glycerin, oder Ester von Fettalkoholen mit Alkansäuren niedriger C-Zahl oder mit Fettsäuren;Fats, waxes and other natural and synthetic fat bodies, preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids;
Alkohole, Diole oder Polyole niedriger C-Zahl, sowie deren Ether, vorzugsweise Ethanol, Isopropanol, Propylenglykol, Glycerin, Ethylenglykol, Ethylenglykolmo- noethyl- oder -monobutylether, Propylenglykolmonomethyl. -monoethyl- oder - monobutylether, Diethylengiykolmonomethyl- oder -monoethylether und analoge Produkte.Alcohols, diols or polyols of low C number, and their ethers, preferably ethanol, isopropanol, propylene glycol, glycerin, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl. monoethyl or monobutyl ether, diethylene glycol monomethyl or monoethyl ether and similar products.
Insbesondere werden Gemische der vorstehend genannten Lösungsmittel verwendet. Bei alkoholischen Lösungsmitteln kann Wasser ein weiterer Bestandteil sein.Mixtures of the abovementioned solvents are used in particular. Water can also be a component of alcoholic solvents.
Erfindungsgemäß verwendete Emulsionen sind vorteilhaft und enthalten z.B. die ge¬ nannten Fette, Öle, Wachse und anderen Fettkörper, sowie Wasser und einen Emul¬ gator, wie er üblicherweise für einen solchen Typ der Formulierung verwendet wird.Emulsions used according to the invention are advantageous and contain e.g. the said fats, oils, waxes and other fat bodies, as well as water and an emulsifier, as is usually used for such a type of formulation.
Erfindungsgemäß verwendete Zubereitungen können auch günstig als Gele vorliegen, die neben den erfindungsgemaßen Wirkstoffkombinationen und dafür üblicherweise ver¬ wendeten Lösemitteln, üblicherweise Alkohole niedriger C-Zahl, z.B. Ethanol, Isopro¬ panol, 1 ,2-Propandiol, Glycerin und Wasser bzw. ein vorstehend genanntes Öl, dann noch organische Verdickungsmittel enthalten, z.B. Gummiarabikum, Xanthangummi, Natriumalginat, Cellulose-Derivate, vorzugsweise Methylcellulose, Hydroxymethylcellu- iose, Hydroxyethylcellulose, Hydroxypropylcellulose, Hydroxypropylmethylcellulose oder anorganische Verdickungsmittel, z.B. Siliciumdioxid und/oder Aluminiumsilikate wie bei¬ spielsweise Bentonite, oder ein Gemisch aus Polyethylenglykol und Polyethylenglykol- stearat oder -distearat. Das oder die Verdickungsmittel sind im Gel z.B. in einer Menge zwischen 0.1 und 30 Gew.-%, bevorzugt zwischen 0,5 und 15 Gew.-%, enthalten.Preparations used according to the invention can also advantageously be present as gels which, in addition to the active compound combinations according to the invention and solvents usually used for them, usually alcohols of low C number, e.g. Ethanol, isopropanol, 1,2-propanediol, glycerol and water or an oil mentioned above, then also contain organic thickeners, e.g. Gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or inorganic thickeners, e.g. Silicon dioxide and / or aluminum silicates such as bentonites, for example, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate. The thickener (s) are in the gel e.g. in an amount between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.
Erfindungsgemäß verwendete feste Stifte enthalten z.B. natürliche oder synthetische Wachse, Fettalkohole oder Fettsäureester. Die erfindungsgemäß verwendeten kosmetischen oder dermatologischen Zubereitungen enthalten bevorzugt 0,0001 - 5,00 Gew.-% einer oder mehrerer Serin-Proteinasen, be¬ zogen auf das Gesamtgewicht der Zubereitungen.Solid sticks used according to the invention contain, for example, natural or synthetic waxes, fatty alcohols or fatty acid esters. The cosmetic or dermatological preparations used according to the invention preferably contain 0.0001-5.00% by weight of one or more serine proteinases, based on the total weight of the preparations.
Es ist vorteilhaft, den erfindungsgemäß verwendeten Zubereitungen weitere gegen Ak¬ ne wirksame Substanzen zuzugeben, beispielsweise gegen Propionibacterium acnes wirksame Stoffe (etwa solche, die in DE-OS 42 29 707, DE-OS 43 05 069, DE-OS 43 07 976, DE-OS 43 37 711 , DE-OS 43 29 379 beschrieben werden) aber auch andere ge¬ gen Akne wirksame Substanzen, beispielsweise all-trans-Retinsäure. 13-cis-Retinsäure und verwandte Stoffe) oder antientzündliche Wirkstoffe, beispielsweise Batylalkohol (α- Octadecylglycerylether), Selachylalkohol (α-9-Octadecenylglycerylether), Chimylalkohol (α-Hexadecylglycerylether) und/oder Bisabolol.It is advantageous to add further substances which are active against acne, for example substances which are active against Propionibacterium acnes (for example those described in DE-OS 42 29 707, DE-OS 43 05 069, DE-OS 43 07 976,) DE-OS 43 37 711, DE-OS 43 29 379) but also other substances which act against acne, for example all-trans-retinoic acid. 13-cis-retinoic acid and related substances) or anti-inflammatory agents, for example batyl alcohol (α-octadecylglyceryl ether), selachyl alcohol (α-9-octadecenylglyceryl ether), chimyl alcohol (α-hexadecylglyceryl ether) and / or bisabolol.
Bevorzugt können die Zubereitungen außerdem Substanzen enthalten, die UV-Strah¬ lung im UVB-Bereich absorbieren, wobei die Gesamtmenge der Filtersubstanzen z.B. 0,1 Gew.-% bis 30 Gew.-%, vorzugsweise 0,5 bis 10 Gew.-%, insbesondere 1 bis 6 Gew.-% beträgt, bezogen auf das Gesamtgewicht der Zubereitungen, um kosmetische und/oder dermatologische Zubereitungen zur Verfügung zu stellen, die die Haut vor dem gesamten Bereich der ultravioletten Strahlung schützen.The preparations can preferably also contain substances which absorb UV radiation in the UVB range, the total amount of filter substances e.g. 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, in particular 1 to 6% by weight, based on the total weight of the preparations, in order to prepare cosmetic and / or dermatological preparations To provide that protect the skin from the entire range of ultraviolet radiation.
Enthalten die erfindungsgemäß verwendeten Zubereitungen UVB-Filtersubstanzen, kön¬ nen diese öllöslich oder wasserlöslich sein. Erfindungsgemäß vorteilhafte öllösliche UVB-Filter sind z.B.:If the preparations used according to the invention contain UVB filter substances, they can be oil-soluble or water-soluble. Oil-soluble UVB filters which are advantageous according to the invention are, for example:
3-Benzylidencampher-Derivate, z.B. 3-(4-Methylbenzyliden)campher, 3-Benzyli- dencampher;3-benzylidene camphor derivatives, e.g. 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
4-Aminobenzoesäure-Derivatθ, z.B. 4-(Dimethylamino)-benzoesäure(2-ethylhexyl)- ester, 4-(Dimethylamino)benzoesäureamylester;4-aminobenzoic acid derivative θ, e.g. 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
Ester der Zimtsäure, z.B. 4-Methoxyzimtsäure(2-ethylhexyl)ester, 4-Methoxyzimt- säureisopentylester;Esters of cinnamic acid, e.g. 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
Ester der Salicylsäure, z.B. Salicylsäure(2-ethylhexyl)ester, Salicylsäure(4-isopro- pylbenzyl)ester, Salicylsäurehomomenthylester,Esters of salicylic acid, e.g. Salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomethyl ester,
Derivate des Benzophenons, z.B. 2-Hydroxy-4-methoxybenzophenon, 2-Hydroxy-Derivatives of benzophenone, e.g. 2-hydroxy-4-methoxybenzophenone, 2-hydroxy
4-methoxy-4'-methylbenzophenon, 2,2'-Dihydroxy-4-methoxybenzophenon;4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone;
Ester der Benzalmalonsäure, z.B. 4-Methoxybenzalmalonsäuredi(2-ethylhexyl)- ester, 2,4,6-Trianilino-(p-carbo-2'-ethyl-1'-hexyloxy) -1,3,5-triazin.Esters of benzalmalonic acid, for example 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester, 2,4,6-trianilino- (p-carbo-2'-ethyl-1'-hexyloxy) -1,3,5-triazine.
Vorteilhafte wasserlösliche UVB-Filter sind z.B.:Advantageous water-soluble UVB filters include:
Salze der 2-Phenylbenzimidazol-5-sulfonsäure wie ihr Natrium-, Kalium- oder ihrSalts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or its
Triethanolammonium-Salz, sowie die Sulfonsäure selbst;Triethanolammonium salt, as well as the sulfonic acid itself;
Sulfonsäure-Derivate von Benzophenonen, wie z.B. 2-Hydroxy-4-methoxybenzo- phenon-5-sulfonsäure und ihre Salze;Sulfonic acid derivatives of benzophenones, e.g. 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its salts;
Sulfonsäure-Derivate des 3-Benzylidencamphers, wie z.B. 4-(2-Oxo-3-bornyliden- methyl)benzolsulfonsäure, 2-Methyl-5-(2-oxo-3-bornylidenmethyl)sulfonsäure und ihre Salze.Sulfonic acid derivatives of 3-benzylidene camphor, e.g. 4- (2-oxo-3-bornylidene-methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidene-methyl) sulfonic acid and their salts.
Enthalten die erfindungsgemäß verwendeten Zubereitungen UVA-Filtersubstanzen, kön¬ nen diese erfindungsgemäß vorteilhaft gewählt werden aus der Gruppe der Derivate des Dibenzoyimethans, z.B. 1-(4'-tert.Butylphenyl)-3-(4'-methoxyphenyl)propan-1 ,3-dion und 1-Phenyl-3-(4'-isopropylphenyl)propan-1 ,3-dion.If the preparations used according to the invention contain UVA filter substances, these can advantageously be selected according to the invention from the group of the derivatives of dibenzoyimethane, e.g. 1- (4'-tert-Butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione and 1-phenyl-3- (4'-isopropylphenyl) propane-1,3-dione.
Die erfindungsgemäß verwendeten Zubereitungen können auch weitere anorganische Pigmente enthalten, die üblicherweise in der Kosmetik zum Schütze der Haut vor UV- Strahlen verwendet werden. Dabei handelt es sich um Oxide des Titans, Eisens, Zirkoni¬ ums, Siliciums, Mangans, Aluminiums, Cers und Mischungen bzw. Abwandlungen da¬ von. Besonders bevorzugt handelt es sich um Pigmente auf der Basis von Titandioxid.The preparations used according to the invention can also contain further inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of titanium, iron, zirconium, silicon, manganese, aluminum, cerium and mixtures or modifications thereof. It is particularly preferred to use pigments based on titanium dioxide.
Insbesondere werden Gemische der vorstehend genannten Lösemittel verwendet. Bei alkoholischen Lösemitteln kann Wasser ein weiterer Bestandteil sein.Mixtures of the abovementioned solvents are used in particular. Water can also be a component of alcoholic solvents.
Es ist von Vorteil, den Tensidgehalt der Formulierungen möglichst gering zu halten, ins¬ besondere geringer als 5 Gew.-%.It is advantageous to keep the surfactant content of the formulations as low as possible, in particular less than 5% by weight.
Ansonsten gelten für diese Gruppe an kosmetischen und/oder dermatologischen Zube¬ reitungen die üblichen Anforderungen, die der Fachmann an solche Zubereitungen und deren Inhaltsstoffe stellt.Otherwise, this group of cosmetic and / or dermatological preparations is subject to the usual requirements which the person skilled in the art places on such preparations and their ingredients.
Die folgenden Beispiele wollen die vorliegende Erfindung erläutern, ohne daß eine Be¬ schränkung auf den Gehalt der Beispiele beabsichtigt ist. Die Mengenangaben bedeu- ten stets, sofern nichts Anderes angegeben ist, Gewichts-%, bezogen auf das Ge¬ samtgewicht der jeweiligen Zubereitungen. The following examples are intended to illustrate the present invention, without any intention to limit the content of the examples. The quantity specifications mean Unless otherwise stated, weight%, based on the total weight of the respective preparations.
Beispiel 1example 1
Akne-TonicAcne tonic
Gew.-%% By weight
Poloxamer 124 10,00Poloxamer 124 10.00
Butylenglycol 20,00Butylene glycol 20.00
PEG-40-hydriertes Rizinusöl 2,00PEG-40 hydrogenated castor oil 2.00
Retinylpalmitat 0,36Retinyl palmitate 0.36
Protease SP 544 0,06Protease SP 544 0.06
Ethanol 20,00Ethanol 20.00
Wasser ad 100,00Water ad 100.00
Beispiel 2Example 2
Akne-TonicAcne tonic
Gew.-%% By weight
Poloxamer 124 10.00Poloxamer 124 10.00
Butylenglycol 20.00Butylene glycol 20.00
Polysorbat 20 2,00Polysorbate 20 2.00
Protease SP 544 0,06Protease SP 544 0.06
Ethanol 20,00Ethanol 20.00
Wasser ad 100,00 Water ad 100.00

Claims

Patentansprüche: Claims:
1. Verwendung von einer oder mehreren Serin-Proteinasen gegen das Erscheinungsbild der unreinen Haut bzw. der Akne.1. Use of one or more serine proteinases against the appearance of blemished skin or acne.
2. Verwendung nach Anspruch 1 , dadurch gekennzeichnet, daß die Serin-Proteinase oder die Serin-Proteinasen in kosmetischen oder dermatologischen Zubereitungen in Konzentrationen von 0,0001 - 5,000 Gew.-% vorliegt, bezogen auf das Gesamtgewicht der Zubereitungen.2. Use according to claim 1, characterized in that the serine proteinase or the serine proteinases is present in cosmetic or dermatological preparations in concentrations of 0.0001 - 5.000% by weight, based on the total weight of the preparations.
3. Verwendung nach Anspruch 2, dadurch gekennzeichnet, daß den Zubereitungen wei¬ tere antientzündliche Wirkstoffe zuzugeben werden, gewählt aus der Gruppe der Anti¬ oxidantien, ferner Batylalkohoi, Selachylalkohol, Chimylalkohol und Bisabolol. 3. Use according to claim 2, characterized in that the preparations further anti-inflammatory agents are added, selected from the group of anti-oxidants, furthermore batyl alcohol, selachyl alcohol, chimyl alcohol and bisabolol.
PCT/EP1996/005703 1996-01-09 1996-12-19 Using serine-proteases for acne and inflamed comedones WO1997025059A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP96944009A EP0876154A1 (en) 1996-01-09 1996-12-19 Using serine-proteases for acne and inflamed comedones
JP9524791A JP2000502717A (en) 1996-01-09 1996-12-19 Use of serine proteinases for acne and inflamed comedones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19600480.2 1996-01-09
DE19600480A DE19600480A1 (en) 1996-01-09 1996-01-09 Use of serine proteinases for acne and inflamed comedones

Publications (1)

Publication Number Publication Date
WO1997025059A1 true WO1997025059A1 (en) 1997-07-17

Family

ID=7782336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/005703 WO1997025059A1 (en) 1996-01-09 1996-12-19 Using serine-proteases for acne and inflamed comedones

Country Status (4)

Country Link
EP (1) EP0876154A1 (en)
JP (1) JP2000502717A (en)
DE (1) DE19600480A1 (en)
WO (1) WO1997025059A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048775A1 (en) * 1997-02-12 1998-11-05 Johnson & Johnson Consumer Companies, Inc. Serine protease and topical retinoid compositions
EP0968707A2 (en) * 1998-07-03 2000-01-05 Beiersdorf Aktiengesellschaft Compositions against acne and inflamed comedones containing serine proteases and one or more calcium salts
JP2014177304A (en) * 2013-02-12 2014-09-25 Brother Ind Ltd Packaging device

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804321B1 (en) * 2000-01-28 2003-08-15 Oreal USE OF POLYAMINOACID DERIVATIVES FOR THE TREATMENT OF SEBORRHEA AND ASSOCIATED SKIN DISORDERS

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004176A1 (en) * 1986-12-03 1988-06-16 David Rudov Pharmaceutical/cosmetic preparation for external application containing an extract from plants of the grass family, in particular of the cereal grasses
WO1993019731A1 (en) * 1992-04-02 1993-10-14 Unilever Plc Skin care method and composition
WO1993019732A1 (en) * 1992-04-02 1993-10-14 Unilever Plc Skin care method and composition
WO1995007688A1 (en) * 1993-09-15 1995-03-23 Unilever Plc Skin care method and composition
WO1995007687A1 (en) * 1993-09-15 1995-03-23 Unilever Plc Skin care method and composition
WO1995007686A1 (en) * 1993-09-15 1995-03-23 Unilever Plc Skin care composition comprising thiol proteases from the stratum corneum
EP0759293A1 (en) * 1995-07-25 1997-02-26 L'oreal Stable composition containing an enzyme

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2096665T3 (en) * 1990-10-16 1997-03-16 John Lezdey INFLAMMATION TREATMENT.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988004176A1 (en) * 1986-12-03 1988-06-16 David Rudov Pharmaceutical/cosmetic preparation for external application containing an extract from plants of the grass family, in particular of the cereal grasses
WO1993019731A1 (en) * 1992-04-02 1993-10-14 Unilever Plc Skin care method and composition
WO1993019732A1 (en) * 1992-04-02 1993-10-14 Unilever Plc Skin care method and composition
WO1995007688A1 (en) * 1993-09-15 1995-03-23 Unilever Plc Skin care method and composition
WO1995007687A1 (en) * 1993-09-15 1995-03-23 Unilever Plc Skin care method and composition
WO1995007686A1 (en) * 1993-09-15 1995-03-23 Unilever Plc Skin care composition comprising thiol proteases from the stratum corneum
EP0759293A1 (en) * 1995-07-25 1997-02-26 L'oreal Stable composition containing an enzyme

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048775A1 (en) * 1997-02-12 1998-11-05 Johnson & Johnson Consumer Companies, Inc. Serine protease and topical retinoid compositions
EP0968707A2 (en) * 1998-07-03 2000-01-05 Beiersdorf Aktiengesellschaft Compositions against acne and inflamed comedones containing serine proteases and one or more calcium salts
EP0968707A3 (en) * 1998-07-03 2003-08-13 Beiersdorf Aktiengesellschaft Compositions against acne and inflamed comedones containing serine proteases and one or more calcium salts
JP2014177304A (en) * 2013-02-12 2014-09-25 Brother Ind Ltd Packaging device

Also Published As

Publication number Publication date
DE19600480A1 (en) 1997-07-10
EP0876154A1 (en) 1998-11-11
JP2000502717A (en) 2000-03-07

Similar Documents

Publication Publication Date Title
EP0770378A1 (en) Cosmetic preparations with an effective amount of glycosylglycerides
WO2001003657A1 (en) Topically applied idebenone-containing agent with protective and regenerative effect
EP1623698A1 (en) Use of a combination comprising one or more bioquinones and one or more isoflavonoids for the improvement of the state of the skin
DE10036797A1 (en) Use of combinations containing carnitines
EP1813255B1 (en) Stable combination of active agents containing glucose derivates and hydroxycarboxylic acids
DE10136077A1 (en) Cosmetic or dermatological preparations containing creatinine and creatine, useful e.g. for combating skin aging symptoms or treating inflammatory conditions such as eczema or psoriasis
EP0769291B1 (en) Active agent combination against acne and inflamed comedones
DE4444237C2 (en) Use of combinations of active ingredients to combat blemished skin caused by Propionibacterium acnes and mild forms of acne
EP1324745A1 (en) Cosmetic or dermatological formulations containing aminoguanidine
DE19802204A1 (en) Cosmetic or pharmacological oil in water emulsions with reduced stickiness
DE19720339A1 (en) Treatment or prevention of undesired skin pigmentation
EP1733741A2 (en) O/W-emulsions comprising one or several bioquinones and an elevated amount of glycerine
EP1414401A1 (en) Utilization of creatinine and/or creatinine derivatives in cosmetic and dermatological preparations
DE19518845A1 (en) Cosmetic or dermatological preparations containing phytic acid
EP0968707A2 (en) Compositions against acne and inflamed comedones containing serine proteases and one or more calcium salts
DE19806946A1 (en) Combination of (acyl) carnitine and retinoid for use in skin care, effective e.g. against light-induced damage and inflammation
EP0876154A1 (en) Using serine-proteases for acne and inflamed comedones
EP1397119A2 (en) Use of sodium polystyrene sulfonate for tightening skin
EP0945127A2 (en) Use of acylcarnitine
DE19518815A1 (en) Cosmetic or dermatological preparations containing alpha-hydroxy fatty acids
EP0706786A2 (en) Use of chlorogenic acid as antioxidant in cosmetic, especially haircosmetic compositions, and compositions containing chlorogenic acid
DE10316666B4 (en) Cosmetic or dermatological preparations with a combination of creatinine with creatine and coenzyme Q10
EP2869811B1 (en) Active ingredient combinations of magnolia bark extract and hyaluronic acid and the cosmetic and/or dermatological use thereof
DE10158076A1 (en) Cosmetic or dermatological compositions, e.g. useful for preventing skin aging or treating inflammatory skin conditions comprise 2-phenoxy-isobutyric acid derivatives
DE10127717A1 (en) Cosmetic or dermatological preparations for combating undesirable skin pigmentation, e.g. in treatment of local hyperpigmentation disorders or cosmetic inhibition of tanning, containing pyridoxine as active agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996944009

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996944009

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996944009

Country of ref document: EP